Gritstone Bio Q3 EPS $(0.33), Inline, Sales $1.56M Miss $1.89M Estimate
Portfolio Pulse from Benzinga Newsdesk
Gritstone Bio reported Q3 losses of $(0.33) per share, in line with analyst consensus. However, the company's quarterly sales of $1.56 million missed the analyst consensus estimate of $1.89 million by 17.20 percent. This represents a 48.20 percent decrease over sales of $3.02 million the same period last year.
November 08, 2023 | 10:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gritstone Bio's Q3 earnings were in line with estimates, but sales missed estimates by 17.20% and decreased 48.20% YoY.
Gritstone Bio's earnings per share met analyst expectations, which is a positive sign. However, the company's sales missed estimates by a significant margin and also decreased significantly compared to the same period last year. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100